Opendata, web and dolomites

RegARcis SIGNED

Role of the SWI/SNF complex in the Androgen Receptor cistrome regulation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "RegARcis" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE 

Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908
website: www.idibell.cat

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 160˙932 €
 EC max contribution 160˙932 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-03-31   to  2022-03-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE ES (L'HOSPITALET DE LLOBREGAT) coordinator 160˙932.00

Map

 Project objective

The significance of epigenetic deregulation is a very hot topic in current prostate cancer (PC) research. New mutations have been identified in several epigenetic regulators known for their interaction with the AR. In fact, the role of chromatin remodeling factors facilitating enhancer-promoter cooperation in the formation of the AR transcriptional complex has long been demonstrated. Accordingly, the marked redistribution of AR binding sites (cistrome) during tumorigenesis is arguably the most recurrent genetic or epigenetic alterations in PC. Thus, this MCSA project aims at elucidating the role of the SWI/SNF chromatin-remodeling complex in the emergence of resistance to anti-AR signaling inhibitors. This is of utmost importance as resistance to AR signaling inhibition is arguably the principle hallmark of lethal prostate cancer. To this end, I aim at (i) investigating the SWI/SNF dependent chromatin accessibility and AR cistrome; and at (ii) assessing the actionability of SWI/SNF interacting partners in castration resistance prostate cancer (CRPC). In short, this MSCA proposal will help to define the repertoire of SWI/SNF coregulators in CRPC and to determine the extent of AR cistrome remodeling to envision new therapeutic strategies and help predict treatment response.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REGARCIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REGARCIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ELOTEQ (2019)

Interfacing Levitated Optomechanics with Superconducting Qubits

Read More  

EDSP (2019)

Engineered dissipation using symmetry-protected superconducting circuits

Read More  

GlycoMabs (2019)

Chemoenzymatic glyco-engineering of therapeutic monoclonal antibodies

Read More  
lastchecktime (2020-11-28 10:02:22) correctly updated